profit from every $100 of sales.
$0$100
Hemab Therapeutics Holdings
$40.86+3.76% today
+20.2% since May 1, 26
1-year low $24.981-year high $54.94
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Hemab Therapeutics Holdings sold, what it kept, and what it did with the cash.
Sales went from $0 in 2024 to $0 in 2025, with -$63.9 million of profit last year.
SalesProfit
Hemab Therapeutics Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Hemab Therapeutics Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Hemab Therapeutics Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2024 | 2025 |
|---|---|---|
| 0 | 0 | |
| – | – | |
| -50 | -70 | |
| -50 | -70 | |
| -49 | -64 | |
| -1.77 | -2.33 | |
| – | – | |
| – | – | |
| – | – |
Balance sheet
| In millions of USD | 2024 | 2025 |
|---|---|---|
| Total assets | 96 | 195 |
| Cash | 74 | 88 |
| Total debt | 2 | 1 |
| Total liabilities | 212 | 371 |
| -115 | -177 | |
| 27 | 27 | |
| – | – | |
| 42.3% | 36.2% |
Cash flow
| In millions of USD | 2024 | 2025 |
|---|---|---|
| -46 | -61 | |
| 0 | 0 | |
| -46 | -61 | |
| Dividends paid | – | – |
| – | – | |
| 2 | 2 |
Valuation
- –
- –
- –
- -11.4×
- –
- –
- –
- -3.2%
- -3.3%
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- +0.0%
Financial health
- -1.2×
- -0.01
- –
- –
- 18.03
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 986
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Hemab Therapeutics Holdings
Is Hemab Therapeutics Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Hemab Therapeutics Holdings AI analysis
What does Hemab Therapeutics Holdings do?
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. It is in Biotechnology.
Does Hemab Therapeutics Holdings pay a dividend?
No. Hemab Therapeutics Holdings does not pay a dividend at the moment.
Is Hemab Therapeutics Holdings stock halal?
Yes. Hemab Therapeutics Holdings passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
Who are Hemab Therapeutics Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Hemab Therapeutics Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.